Results 121 to 130 of about 5,801 (166)
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2. [PDF]
J Clin InvestEsmaeili S +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
A Nanopore Based Molnupiravir Sensor
ACS Sensors, 2022Nucleoside analogues are reagents that resemble the structure of natural nucleosides and are widely applied in antiviral and anticancer therapy. Molnupiravir, a recently reported nucleoside analogue drug, has shown its inhibitory effect against SARS-CoV-2.
Wendong Jia +5 more
openaire +2 more sources
Molnupiravir for the treatment of COVID-19
Drugs of Today, 2022Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate.
Bela G, Santani +2 more
openaire +2 more sources
Molnupiravir in COVID-19: A Scoping Review
Current Drug Research Reviews, 2022Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity.
Atal S
exaly +3 more sources
Molnupiravir is effective in patients with haematological malignancies
International Journal of Cancer, 2023AbstractPatients with hematologic malignancies are particularly vulnerable to severe infectious complications. SARS‐CoV‐2 infection is associated with a high risk of severe course and death in this patient population. In addition, immune deficits associated with both the blood cancer and the treatment used make vaccination against SARS‐CoV‐2 less ...
Łukasz Bołkun +16 more
openaire +2 more sources